| P/E (FY) | — | Sales (TTM) | $5.7M |
| Earnings (TTM) | -$15.9M | ROE | −301.83% |
| Net Margin | −241.96% | ROIC | −718.59% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −3.70% |
| Market Cap | $2.8M | Trading Days | 972 |
| 52W High | 13.64 |
| 52W Low | 0.60 |
| % Off High | −95.39% |
| YTD | −46.75% | 1Y | −93.83% |
| 3Y | −98.87% | Since incept. (ann.) | −77.55% |
Laboratory Services 50% · Health Care Patient Service 40% · Histology Service Fees 9% · Medical Director Fees 1% · …
| Ann. Volatility (1Y) | 193.96% | Ann. Volatility (3Y) | 241.62% |
| Sharpe (1Y) | −0.65 | Sharpe (3Y) | 0.09 |
| Max Drawdown (1Y) | −94.08% | Max Drawdown (3Y) | −99.31% |
| Beta (3Y, vs SPY) | −2.91 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ONMD | OneMedNet Corp | $38.6M | — |
| MXCT | MAXCYTE, INC. | $112.5M | — |
| OABI | OmniAb, Inc. | $285.6M | — |
| NRC | NRC HEALTH | $503.5M | 43.4 |
| ABSI | Absci Corp | $1.11B | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $11.58B | — |
| MEDP | Medpace Holdings, Inc. | $15.94B | 37.4 |
| INCY | INCYTE CORP | $25.96B | 20.3 |
| IQV | IQVIA HOLDINGS INC. | $40.55B | 31.0 |
| FOXO | FOXO TECHNOLOGIES INC. | — | — |
| EPIS-B.ST | Episurf Medical AB | $2.8M | — |
| CELZ |
| $2.7M |
| — |
